Medical Policies and Clinical Utilization Management Guidelines Update

May 26, 2021
group-label
Button Group
size
md
orientation
horizontal
alignment
center
button-type
lh-button
variant
text
text
Medical Policy & Clinical Guidelines
media-label
label
link
Medical Policy & Clinical Guidelines
icon-position
right
full-width
false
full-width-mobile
false

Please note, this communication applies to Healthy Blue + Medicare℠ (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).

The Medical Policies, Clinical Utilization Management (UM) Guidelines and Third Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed.  Please note:  The Medical Policies and Clinical UM Guidelines below are followed in the absence of Medicare guidance.

Please share this notice with other members of your practice and office staff.

To view a guideline, visit https://medpol.providers.amerigroup.com/green-provider/medical-policies-and-clinical-guidelines-full-list.

Notes/Updates:

Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.

  • *CG-LAB-15 – Red Blood Cell Folic Acid Testing

    • RBC folic acid testing is considered not medically necessary in all cases
  • *CG-LAB-16 – Serum Amylase Testing

    • Serum amylase testing is considered not medically necessary for acute and chronic pancreatitis and all other conditions
  • *CG-GENE-04 – Molecular Marker Evaluation of Thyroid Nodules

    • Added the Afirma Xpression Atlas as not medically necessary
  • SURG.00158 – Implantable Peripheral Nerve Stimulation Devices as a Treatment for Pain

    • A new Medical Policy was created from content contained in DME.00011
    • There are no changes to the policy content.
    • Publish date is December 16, 2020.
  • CG-GENE-21 – Cell-Free Fetal DNA-Based Prenatal Testing

    • A new Clinical Guideline was created from content contained in GENE.00026
    • There are no changes to the guideline content.
    • Publish date is December 16, 2020.

Medical Policies

On November 5, 2020, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Blue Cross NC. These guidelines take effect June 8, 2021.

lh-header-fill
true
lh-sticky-header-column
true
PUBLISH DATE MEDICAL POLICY NUMBER MEDICAL POLICY TITLE NEW OR REVISED
11/12/2020 ANC.00009 Cosmetic and Reconstructive Services of the Trunk and Groin Revised
11/12/2020 GENE.00052 Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling Revised
11/12/2020 MED.00129 Gene Therapy for Spinal Muscular Atrophy Revised
12/16/2020 SURG.00011 Allogeneic, Xenographic, Synthetic and Composite Products for Wound Healing and Soft Tissue Grafting Revised

Clinical UM Guidelines

On November 5, 2020, the MPTAC approved the following Clinical UM Guidelines applicable to Blue Cross NC. These guidelines adopted by the medical operations committee for Blue Cross NC members on November 19, 2020. These guidelines take effect June 8, 2021.

lh-header-fill
true
lh-sticky-header-column
true
PUBLISH DATE CLINICAL UM GUIDELINE NUMBER CLINICAL UM GUIDELINE TITLE NEW OR REVISED
12/16/2020 *CG-LAB-15 Red Blood Cell Folic Acid Testing New
12/16/2020 *CG-LAB-16 Serum Amylase Testing New
11/12/2020 CG-DME-42 Non-implantable Insulin Infusion and Blood Glucose Monitoring Devices Revised
12/16/2020 *CG-GENE-04 Molecular Marker Evaluation of Thyroid Nodules Revised
12/16/2020 CG-GENE-18 Genetic Testing for TP53 Mutations Revised
12/16/2020 CG-GENE-20 Epidermal Growth Factor Receptor (EGFR) Testing Revised
11/12/2020 CG-MED-87 Single Photon Emission Computed Tomography Scans for Noncardiovascular Indications Revised